Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 6/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 1.00 |
| ▸ | BLM | P54132 | 4/20 | 1.00 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | HTR1A | P08908 | 2/20 | 1.00 |
| ▸ | THPO | P40225 | 2/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | NMUR2 | Q9GZQ4 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | ADRB2 | P07550 | 5/20 | 0.63 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.63 |
| ▸ | ADRA2B | P18089 | 4/20 | 0.63 |
| ▸ | ADRA2C | P18825 | 4/20 | 0.63 |
| ▸ | TSHR | P16473 | 4/20 | 0.63 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.63 |
| ▸ | ADRB3 | P13945 | 3/20 | 0.63 |
| ▸ | MAPT | P10636 | 3/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxedrine SCHEMBL146500 | 1.00 | KDM4E (1.00) | KDM4EHIF1ATDP1BLMTAAR1 | |
| Oxedrine SCHEMBL17726874 | 1.00 | KDM4E (1.00) | KDM4EHIF1ATDP1BLMTAAR1 | |
| Oxedrine SCHEMBL28287981 | 1.00 | KDM4E (1.00) | KDM4EHIF1ATDP1BLMTAAR1 | |
| Oxedrine SCHEMBL1487703 | 0.98 | KDM4E (0.96) | KDM4EHIF1ATDP1BLMTAAR1 | |
| SCHEMBL28858225 | 0.94 | HIF1A (0.89) | KDM4EHIF1ATDP1BLMTAAR1 | |
| SCHEMBL28193633 | 0.94 | HIF1A (0.89) | KDM4EHIF1ATDP1BLMTAAR1 | |
| Oxedrine SCHEMBL28002395 | 0.91 | HIF1A (0.82) | KDM4EHIF1ATDP1BLMTAAR1 | |
| Oxedrine SCHEMBL30559825 | 0.88 | KDM4E (0.77) | KDM4EHIF1ATDP1BLMTAAR1 | |
| Oxedrine SCHEMBL146499 | 0.88 | KDM4E (0.77) | KDM4EHIF1ATDP1BLMTAAR1 | |
| Halostachine SCHEMBL28853304 | 0.86 | HIF1A (0.75) | KDM4EHIF1ATDP1BLMTAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260041652-A1 | SYSTEM AND METHOD FOR PREVENTING ALOPECIA | FOLLEA INT (US) | 2026-02-12 | — | — | US | claimed |
| WO-2024118094-A1 | SYSTEM AND METHOD FOR PREVENTING ALOPECIA | FOLLEA INTERNATIONAL (US) | 2024-06-06 | — | — | WO | claimed |
| CN-107427479-B | System and method for preventing hair loss | 芙丽雅国际公司 | 2021-03-30 | — | — | CN | claimed |
| EP-3217967-B1 | SYSTEM AND METHOD FOR PREVENTING ALOPECIA | FOLLEA INT (US) | 2019-09-18 | — | — | EP | claimed |
| US-10238593-B2 | System and method for preventing alopecia | FOLLEA INTERNATIONAL (US) | 2019-03-26 | — | — | US | claimed |
| CN-107427479-A | The system and method for anti-alopecia-stopping | 芙丽雅国际公司 | 2017-12-01 | — | — | CN | claimed |
| US-20170333316-A1 | SYSTEM AND METHOD FOR PREVENTING ALOPECIA | FOLLEA INTERNATIONAL (US) | 2017-11-23 | — | — | US | claimed |
| EP-3217967-A1 | SYSTEM AND METHOD FOR PREVENTING ALOPECIA | Follea International (US) | 2017-09-20 | — | — | EP | claimed |
| WO-2016077744-A1 | SYSTEM AND METHOD FOR PREVENTING ALOPECIA | GOREN OFER A (US) | 2016-05-19 | — | — | WO | claimed |
| WO-2026106796-A1 | SYSTEM AND METHOD FOR THE TREATMENT OF TELOGEN EFFLUVIUM, ANDROGENETIC ALOPECIA, AND OTHER HAIR LOSS DISORDERS | FOLLEA INTERNATIONAL (US) | 2026-05-21 | — | — | WO | disclosed |
| US-20260041652-A1 | SYSTEM AND METHOD FOR PREVENTING ALOPECIA | FOLLEA INT (US) | 2026-02-12 | — | — | US | disclosed |
| WO-2024118094-A1 | SYSTEM AND METHOD FOR PREVENTING ALOPECIA | FOLLEA INTERNATIONAL (US) | 2024-06-06 | — | — | WO | disclosed |
| US-20230338309-A1 | COMPOSITIONS AND METHODS FOR TOPICAL TREATMENT OF VASCULAR CONDITIONS | JSS RESEARCH, LLC | 2023-10-26 | — | — | US | disclosed |
| CN-116930388-A | Method for screening brain tissue markers of Parkinson model mice based on metabonomics | 苏州大学附属第二医院 | 2023-10-24 | — | — | CN | disclosed |
| WO-2011103130-A1 | AMINOTHIAZOLONES AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-08-25 | — | — | WO | disclosed |
| US-20110200586-A1 | AMINOTHIAZOLONES AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-08-18 | — | — | US | disclosed |
| CN-102040529-A | Method for synthesizing synephrine hydrochloride | HANGZHOU FST PHARMACEUTICAL CO LTD | 2011-05-04 | — | — | CN | disclosed |
| CN-101792394-A | Extraction separation method of L-synephrine | UNIV CHONGQING | 2010-08-04 | — | — | CN | disclosed |
| CN-1031643-C | Novel glycoside compounds and production and use thereof | HARRIER INC (US) | 1996-04-24 | — | — | CN | disclosed |
| CN-1073179-A | Novel glycoside compounds and preparation thereof and purposes | HARRIER INC (US) | 1993-06-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260041652-A1 | SYSTEM AND METHOD FOR PREVENTING ALOPECIA | DYRK4, DYRK2, STRA6 | KDM4E 1963/4885HIF1A 3522/4885TDP1 906/4885 |
| US-20110200586-A1 | AMINOTHIAZOLONES AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS | ESR2, ESRRA, ESRRG | KDM4E 2936/4885HIF1A 186/4885TDP1 2709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.